Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Madrigal Pharmaceuticals stock has pulled back in recent weeks after a very strong multi year run, which leaves investors asking whether the current price still looks attractive based on the broader valuation checks.
- Over the past 5 years the share price has delivered a very large gain of about 5.4x, which means even small changes in expectations can now matter much more for valuation.
- Future expectations for Madrigal Pharmaceuticals often hinge on how successfully it can convert its pipeline and products into durable cash flows, while any setback in execution or funding needs may weigh heavily on what investors are willing to pay.
- Madrigal Pharmaceuticals currently passes 5 out of 6 valuation checks. This means the broader framework on valuation leans toward the stock looking undervalued on several measures.
The issue now is whether Madrigal Pharmaceuticals’ recent pullback has reset expectations enough for the current price to be supported by those underlying valuation checks.
Is Madrigal Pharmaceuticals a Bargain on Sales?
P/S is often the cleaner check for Madrigal Pharmaceuticals because it focuses on how the market values each dollar of current sales. This can be useful for biotechs that are still working toward consistent profitability.
Madrigal Pharmaceuticals trades on a P/S of about 9.4x. This sits below the broader biotech industry average of around 11.1x and well below the selected peer group average of about 28.3x. A tailored fair P/S multiple for the company is estimated at roughly 15.0x, which sits between the industry and peer marks and reflects its specific mix of scale, risks and revenue profile.
Against that fair ratio, the current 9.4x P/S suggests the stock price does not fully reflect the revenue base implied by that framework. Investors who focus on sales based valuation may see the recent pullback as having opened a gap between price and this P/S yardstick.
On this P/S check, Madrigal Pharmaceuticals stock appears undervalued relative to the fair multiple implied by its profile.
See what the numbers say about this price — find out in our valuation breakdown.
The Madrigal Pharmaceuticals Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Madrigal Pharmaceuticals help you connect the recent valuation checks to concrete future paths for the business. Each scenario spells out what would need to happen to Madrigal Pharmaceuticals' growth, margins and earnings for the stock to be worth materially more or less than today's price, and ties its number to a specific view of how growth, profitability and risks could evolve. You can then revisit that view on the Community page as new information emerges.
One of the top community narratives on Madrigal Pharmaceuticals: 23% undervalued
"Upcoming international expansion, beginning with the imminent launch in Germany and broader EU approval, positions the company to tap into new, underpenetrated markets…"
Read one of the top narratives on Madrigal Pharmaceuticals
Do you think there's more to the story for Madrigal Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
Madrigal Pharmaceuticals currently screens as undervalued on the sales based framework, especially when compared with both industry and peer P/S multiples. The recent sharp share price move means small shifts in expectations around execution and funding can have an outsized impact from here. The key question for you is whether Madrigal Pharmaceuticals can turn its current revenue base into durable cash flows that justify a higher multiple, or whether the discount simply reflects the risks of that transition.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com